The mammalian small RNA machinery and its role in antiviral defenses

哺乳动物小RNA机制及其在抗病毒防御中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Understanding the molecular basis for why viruses cause disease is an essential requirement for future development of antiviral therapeutics. While we know a great deal about how viruses are recognized and the various ways in which they are combated, there are still vast areas of cellular antiviral immunity that remain unknown. This research proposal focuses on one such area. The central question being addressed in this proposal is whether small RNAs, or components of the mammalian small RNA machinery, contribute to the cellular response to infection. The importance of this question and the need to address it experimentally can be justified through extensive preliminary data that suggest a novel means to combat virus infection is present in mammalian cells but awaits characterization. In an effort to understand the interplay between the small RNA pathway of mammals and the response to virus infection we have discovered the potency by which the RNA induced silencing complex (RISC) can inhibit virus replication, isolated the first mammalian virus protein which inhibits RISC function, and found that Drosha, a key player in small RNA biogenesis, actively translocates to the cytoplasm during RNA virus infection. Taken together, we believe this research provides compelling evidence for an unappreciated small RNA-mediated antiviral response in mammals. Here we propose to use the virus antagonist to RISC (called VP55) to define the small RNA response to infection in vivo as well as characterize how Drosha participates in this antiviral activity. The overall objective of this proposal is to delineate howthe small RNA pathway contributes to our response to virus infection.
描述(由申请人提供):了解病毒引起疾病的分子基础是未来开发抗病毒疗法的基本要求。尽管我们对病毒的识别方式以及对抗病毒的各种方式了解很多,但细胞抗病毒免疫仍有大量领域仍不清楚。本研究提案重点关注这样一个领域。该提案要解决的核心问题是小RNA或哺乳动物小RNA机器的组成部分是否有助于细胞对感染的反应。这个问题的重要性以及通过实验解决这个问题的必要性可以通过大量的初步数据来证明,这些数据表明哺乳动物细胞中存在一种对抗病毒感染的新方法,但有待表征。为了了解哺乳动物的小RNA途径与对病毒感染的反应之间的相互作用,我们发现了RNA诱导沉默复合物(RISC)抑制病毒复制的效力,分离了第一个抑制RISC功能的哺乳动物病毒蛋白,并发现小RNA生物发生的关键参与者Drosha在RNA病毒感染期间主动易位到细胞质。总而言之,我们相信这项研究为哺乳动物中未被重视的小 RNA 介导的抗病毒反应提供了令人信服的证据。在这里,我们建议使用 RISC 的病毒拮抗剂(称为 VP55)来定义小 RNA 对体内感染的反应,并描述 Drosha 如何参与这种抗病毒活性。该提案的总体目标是描述小 RNA 途径如何有助于我们对病毒感染的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Benjamin R. tenOever其他文献

RNA viruses and the host microRNA machinery
RNA 病毒与宿主微小 RNA 机制
  • DOI:
    10.1038/nrmicro2971
  • 发表时间:
    2013-02-15
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Benjamin R. tenOever
  • 通讯作者:
    Benjamin R. tenOever

Benjamin R. tenOever的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Benjamin R. tenOever', 18)}}的其他基金

Defining the Biology of the ADAR1-RISC Complex
定义 ADAR1-RISC 复合体的生物学
  • 批准号:
    10879449
  • 财政年份:
    2022
  • 资助金额:
    $ 41.83万
  • 项目类别:
Defining the Biology of the ADAR1-RISC Complex
定义 ADAR1-RISC 复合体的生物学
  • 批准号:
    10494390
  • 财政年份:
    2022
  • 资助金额:
    $ 41.83万
  • 项目类别:
Characterizing a transcriptional control region within the Type I interferon gene cluster
表征 I 型干扰素基因簇内的转录控制区域
  • 批准号:
    10624947
  • 财政年份:
    2022
  • 资助金额:
    $ 41.83万
  • 项目类别:
Characterizing a transcriptional control region within the Type I interferon gene cluster
表征 I 型干扰素基因簇内的转录控制区域
  • 批准号:
    10506860
  • 财政年份:
    2022
  • 资助金额:
    $ 41.83万
  • 项目类别:
Defining the Biology of the ADAR1-RISC Complex
定义 ADAR1-RISC 复合体的生物学
  • 批准号:
    10631184
  • 财政年份:
    2022
  • 资助金额:
    $ 41.83万
  • 项目类别:
Small viral RNAs as determinants of influenza A virus pathogenesis
小病毒 RNA 作为甲型流感病毒发病机制的决定因素
  • 批准号:
    10557136
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
Small viral RNAs as determinants of influenza A virus pathogenesis
小病毒 RNA 作为甲型流感病毒发病机制的决定因素
  • 批准号:
    10524881
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
Small viral RNAs as determinants of influenza A virus pathogenesis
小病毒 RNA 作为甲型流感病毒发病机制的决定因素
  • 批准号:
    10097984
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
Stemness and the cellular response to virus infection
干性和细胞对病毒感染的反应
  • 批准号:
    9528170
  • 财政年份:
    2018
  • 资助金额:
    $ 41.83万
  • 项目类别:
The biology of the nuclear export protein in influenza A virus replication
甲型流感病毒复制中核输出蛋白的生物学
  • 批准号:
    9975684
  • 财政年份:
    2017
  • 资助金额:
    $ 41.83万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 41.83万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 41.83万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 41.83万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 41.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 41.83万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 41.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了